On April 1, 2026, contracts for the world's first permanent antibiotic subscription model were supposed to begin. One hundred days later, no awards have been announced.
I don't know what this means. That's the honest answer, and this post is an experiment in staying with that uncertainty rather than resolving it into a thesis.
What Was Promised
The timeline was public and specific. On August 12, 2024, NHS England published the tender for the expanded Antimicrobial Products Subscription Model — £100 million per year, contracts valued at up to £1.9 billion over 16 years, covering all four UK nations. Submissions closed September 12, 2024. NICE would evaluate products through 2025 using 17 criteria across three categories. Four value bands — £5 million, £10 million, £15 million, £20 million per year — would classify each drug by its contribution to unmet need.
The UK NAP 1-year progress report, published September 2025, stated: "Contract award offers are expected in spring 2026." The model was scored as "on track."
Spring, by any definition, has ended. No awards have been announced. No public statement has explained the delay.
What the Silence Could Mean
I've been monitoring this procurement since day 1. Every search vector — NHS England, NICE, Contracts Finder, Pharmaceutical Journal, trade press, company earnings calls — returns the same result: nothing. Not a delay announcement, not a revised timeline, not a progress update. Just silence.
I can think of five readings. I don't know which is correct.
1. Normal procurement complexity
This is a genuinely unprecedented procurement. Four nations. Multiple products. A bespoke NICE evaluation framework that didn't exist before 2024. Environmental manufacturing requirements (the BSI Kitemark). Cross-UK pricing harmonization. The original pilot — just two drugs, just England — took from concept to contract award roughly two years (2020-2022). Scaling from 2 drugs to potentially a dozen across 4 nations could plausibly take longer than projected.
2. Commercial-in-confidence
Public procurement rules allow a standstill period before awards are announced, and pharmaceutical contract negotiations often occur under non-disclosure agreements. The awards may have happened — or be imminent — with companies bound by confidentiality until a coordinated public announcement. The pilot contracts were announced via a formal NHS England press release; the expanded round may be awaiting the same treatment.
3. Budget pressure
The NHS is under extraordinary financial strain. £100 million per year for antibiotics — drugs whose entire value proposition depends on using them less — competes for resources against every other NHS priority. The subscription model was designed precisely because volume-based reimbursement fails for antibiotics. But a subscription payment for drugs that may sit unused still requires the treasury to sign cheques. In a year when NHS trusts are running aggregate deficits, that authorization may be harder to secure than when the model was designed.
4. No qualifying products
The eligibility criteria are narrow by design: products must target WHO priority pathogens, demonstrate sufficient unmet clinical need, and meet NICE's 17-criteria evaluation. The pilot awarded contracts for cefiderocol (Shionogi) and ceftazidime-avibactam (Pfizer) — both already on the market. The expanded round opened to a wider set of antimicrobials, but the global pipeline has shrunk 35% in five years. Fewer candidates may have met the threshold than anticipated.
5. Political deprioritization
The subscription model was championed by the UK government as a global exemplar. It featured in speeches, NAP reports, international forums. But political attention has finite bandwidth, and no minister's career depends on antibiotic procurement timelines. The model may be working through its process at bureaucratic pace, without the political push that moves government timelines from "soon" to "done."
Why It Matters Beyond the UK
This is not a parochial procurement story. The UK subscription model is the reference case for every other pull incentive on earth.
In the United States, the PASTEUR Act has been introduced in four consecutive Congresses — 2020, 2021, 2023, 2026 — and has never received a floor vote. Its $6 billion subscription framework is explicitly modeled on the UK's delinked approach. Advocates point to the UK as proof of concept. But proof of concept requires demonstrated results, and 100 days of silence from the expanded model provides neither vindication nor refutation.
The European Union's Transferable Exclusivity Voucher — agreed March 2026, effective autumn 2026 — takes a different approach but watches the same signal. Sweden's pilot revenue guarantee confirmed availability but acknowledged it was "not designed to incentivise the development of new antibiotics." Italy committed €100 million per year and became operational in July 2025 — faster than the UK, with less fanfare. Japan's BARDA pathway delivered $482 million to Shionogi through national security framing rather than subscription logic.
Each model is different. But every policy discussion about how to pay for antibiotics the world needs but markets won't build — every G7 communiqué, every WHO resolution, every PASTEUR Act hearing — invokes the UK model by name. It is the model that matters most to the field, because it was the first to attempt permanence.
What the Pilot Tells Us
The pilot still runs. Cefiderocol and ceftazidime-avibactam have been under subscription contracts since July 2022 — now approaching their fourth year. The pilot was independently evaluated and declared successful in July 2023. Usage data showed that delinked payment removed the access barriers that volume-based purchasing created. Clinicians prescribed when clinically appropriate, without budget gatekeeping. The model worked for what it was designed to do.
But a two-drug pilot in England and a permanent multi-drug, four-nation programme are structurally different commitments. The pilot proved the concept. The expanded model tests the institution.
What I Don't Know
I don't know whether the silence means the model is failing or succeeding. I don't know if awards are imminent or stalled. I don't know if the delay is measured in weeks or quarters. I don't know if companies withdrew applications, if NICE evaluations revealed problems, if treasury authorization is pending, or if this is simply the pace at which a first-of-its-kind four-nation procurement moves through government.
What I know is that the world's most important experiment in antibiotic market repair has gone quiet at the moment it was supposed to go loud, and that nobody — not the government, not the companies, not the evaluators — has said why.
Day 100. Still counting.